Stockscreener 앱 받기
7.25
5.84%
0.40
시간 외 거래:
7.25
전일 마감가:
$6.85
열려 있는:
$6.91
하루 거래량:
146.17K
Relative Volume:
0.75
시가총액:
$263.13M
수익:
$16.10M
순이익/손실:
$-42.57M
주가수익비율:
-5.1408
EPS:
-1.4103
순현금흐름:
$-38.53M
1주 성능:
+8.21%
1개월 성능:
+21.85%
6개월 성능:
+12.84%
1년 성능:
+56.59%
1일 변동 폭
$6.8573
$7.5296
1주일 범위
$6.61
$7.8899
52주 변동 폭
$3.76
$8.95
프로파운드 메디컬 Stock (PROF) Company Profile
명칭
Profound Medical Corp
전화
647-476-1350
주소
2400 SKYMARK AVENUE, UNIT 6, MISSISSAUGA, ON
Compare PROF vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PROF
Profound Medical Corp
|
7.25 | 248.61M | 16.10M | -42.57M | -38.53M | -1.4103 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
프로파운드 메디컬 Stock (PROF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-23 | 개시 | Lake Street | Buy |
| 2024-07-16 | 업그레이드 | Stifel | Hold → Buy |
| 2023-11-28 | 개시 | Stifel | Hold |
| 2023-08-04 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-03-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-09-15 | 개시 | Jefferies | Buy |
모두보기
프로파운드 메디컬 주식(PROF)의 최신 뉴스
Profound Medical (PROF) price target decreased by 26.77% to 8.49 - MSN
Profound outlines ~$25M 2026 revenue, anticipates FDA clearance for Siemens Free integration by year-end - MSN
Profound Medical Q1 Earnings Call Highlights - Barchart.com
Profound Medical revenue up 104% in Q1 2026 - Medical Buyer
Earnings call transcript: Profound Medical beats Q1 2026 forecasts By Investing.com - Investing.com Australia
Earnings call transcript: Profound Medical beats Q1 2026 forecasts - Investing.com
Profound Medical Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Profound Medical : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Profound Medical Reports Strong First Quarter 2026 Financial Results - Investing News Network
Profound Medical Down 8.5% After Hours as Its Q1 Loss Narrows, Revenue More Than Doubles, Beats Estimates - marketscreener.com
Profound Medical Issues FY26 Revenue Guidance and Announces Humana Is Now Covering the TULSA Procedure - marketscreener.com
Profound Medical Says Q1 Results Marked By 104% Revenue Growth and "Improved" Operating Performance - marketscreener.com
Profound Medical Q1 Basic and Diluted Net Loss Per Common Share US$0.19, Vs $0.36 a Year Ago - marketscreener.com
Humana starts covering Profound's TULSA procedure as revenue jumps 104% - Stock Titan
Profound Medical (NASDAQ: PROF) doubles Q1 revenue as losses narrow - Stock Titan
Profound Medical (NASDAQ: PROF) posts 104% Q1 2026 revenue growth - Stock Titan
When Will Profound Medical Corp. (TSE:PRN) Turn A Profit? - simplywall.st
Profound Medical : Investor Presentation (Profound Investor Presentation May 2026 ver1) - marketscreener.com
Profound Medical Corp (PROF) Q1 2026 Earnings Report Preview: Wh - GuruFocus
Profound Medical Corp. (TSE:PRN) Is Expected To Breakeven In The Near Future - Yahoo Finance
Profound Medical Corp (PROF) Q4 2025 Earnings Call Highlights: R - GuruFocus
MSN Money - MSN
Why Medtech Giants Are Quietly Paying Up for AI Diagnostics - Benzinga
Why Medtech Giants Are Quietly Paying Up for AI Diagnostics - Sahm
Profound Medical Showcases TULSA Data, AI Software Upgrades, and Reimbursement Tailwinds at Conference - Yahoo Finance
Profound Medical (TSX:PRN) Stock Price & News - The Motley Fool Canada
Responsive Playbooks and the PROF Inflection - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp.PROF - FinancialContent
Profound Medical : Investor Presentation (Profound Investor Presentation April 2026 ver9final) - marketscreener.com
Profound Medical : Investor Presentation (Profound Investor Presentation April 2026 ver8final) - marketscreener.com
Profound Medical (PROF) Stock: Year Start (Institutional Demand) 2026-04-20Stock Community Signals - newser.com
Profound Medical to Release First Quarter 2026 Financial Results on May 7Conference Call to Follow - Investing News Network
Profound Medical : FY 2025 Management Information Circular - marketscreener.com
Profound Medical Schedules First-Quarter 2026 Earnings Release - TipRanks
Profound Medical to report Q1 2026 results May 7, conference call at 4:30 p.m. ET - TradingView
Profound Medical (NASDAQ: PROF) to report Q1 2026 results, host call May 7 - Stock Titan
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow - Toronto Star
Profound Medical (PROF) Stock: Momentum Signals (Smart Money Active) 2026-04-15Community Sell Signals - UBND thành phố Hải Phòng
PROF SEC FilingsProfound Med Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Profound Medical Corp. - Mena FN
Stocks in play: Profound Medical Corp. - The Globe and Mail
Profound Medical to Present Business Update at Conference - TipRanks
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference - The Manila Times
Profound Medical (NASDAQ: PROF) plans business update at 2026 Bloom Burton healthcare investor conference - Stock Titan
Income Plays: Is Profound Medical Corp trading at a discountRisk Management & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Aug Analyst Calls: Is Profound Medical Corp showing insider buying2026 Technicals & Expert-Curated Trade Recommendations - baoquankhu1.vn
Buy Signal: Is Profound Medical Corp in a bullish channel2026 Momentum & Low Risk Growth Stock Ideas - baoquankhu1.vn
Understanding the Setup: (PROF) and Scalable Risk - Stock Traders Daily
If You Invested $1,000 in Profound Med Corp (PROF) - Stock Titan
Rate Cut: What hedge funds are buying Profound Medical Corp2026 Gainers & AI Driven Price Predictions - baoquankhu1.vn
Profound Medical Corp. Investigated by the Portnoy Law Firm - GlobeNewswire
프로파운드 메디컬 (PROF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.34%
자본화:
|
볼륨(24시간):